Enhancement of the enzymatic activity of activated coagulation factor IX by anti-factor IX antibodies

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 2, 2008, Pages 315-322

  Scheiflinger, Friedrich ^a   Dockal, M ^a   Rosing, J ^b   Kerschbaumer, R J ^a  

^a BAXTER BIOSCIENCE   (Austria)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Anti FIX antibodies; Factor VIII; FVIII mimetic; Hemophilia A; Procoagulant antibody

Indexed keywords

BLOOD CLOTTING FACTOR 8A; BLOOD CLOTTING FACTOR 9A; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; PROTEINASE; THROMBIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY ISOLATION; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; BINDING COMPETITION; BINDING KINETICS; BLOOD CLOTTING; BLOOD LEVEL; COMPLEX FORMATION; CONTROLLED STUDY; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME SUBSTRATE; HEMOPHILIA A; HYBRIDOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION;

EID: 38349137399     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.02868.x     Document Type: Article

References (26)

1. Mann KG. Biochemistry and physiology of blood coagulation. Thromb Haemost 1999; 82: 165-74.
2. van Dieijen G, Tans G, Rosing J, Hemker HC. The role of phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem 1981; 256: 3433-42.
3. Fay PJ. Activation of factor VIII and mechanisms of cofactor action. Blood Rev 2004; 18: 1-15.
4. Fay PJ, Jenkins PV. Mutating factor VIII: Lessons from structure to function. Blood Rev 2005; 19: 15-27.
5. Autin L, Miteva MA, Lee WH, Mertens K, Radtke KP, Villoutreix BO. Molecular models of the procoagulant factor VIIIa-factor IXa complex. J Thromb Haemost 2005; 3: 2044-56.
6. Kolkman JA, Mertens K. Insertion loop 256-268 in coagulation factor IX restricts enzymatic activity in the absence but not in the presence of factor VIII. Biochemistry 2000; 39: 7398-405.
7. Lapan KA, Fay PJ. Localization of a factor X interactive site in the A1 subunit of factor VIIIa. J Biol Chem 1997; 272: 2082-8.
8. van Dieijen G, van Rijn JL, Govers-Riemslag JW, Hemker HC, Rosing J. Assembly of the intrinsic factor X activating complex - interactions between factor IXa, factor VIIIa and phospholipid. Thromb Haemost 1985; 53: 396-400.
9. Ahmad SS, London FS, Walsh PN. Binding studies of the enzyme (factor IXa) with the cofactor (factor VIIIa) in the assembly of factor-X activating complex on the activated platelet surface. J Thromb Haemost 2003; 1: 2348-55.
10. Rosing J, van Rijn JL, Bevers EM, van Dieijen G, Comfurius P, Zwaal RF. The role of activated human platelets in prothrombin and factor X activation. Blood 1985; 65: 319-32.
11. Fay PJ, Koshibu K. The A2 subunit of factor VIIIa modulates the active site of factor IXa. J Biol Chem 1998; 273: 19049-54.
12. Brettler DB. Inhibitors in congenital haemophilia. Baillieres Clin Haematol 1996; 9: 319-29.
13. Penner JA. Haemophilic patients with inhibitors to factor VIII or IX: variables affecting treatment response. Haemophilia 2001; 7: 103-8.
14. Monfardini C, Kieber-Emmons T, VonFeldt JM, Godillot AP, Voet D, Weiner DB, Williams WV. Rational design, analysis, and potential utility of GM-CSF antagonists. Proc Assoc Am Physicians 1996; 108: 420-31.
15. Magliani W, Conti S, Salati A, Vaccari S, Ravanetti L, Maffei DL, Polonelli L. Therapeutic potential of yeast killer toxin-like antibodies and mimotopes. FEMS Yeast Res 2004; 5: 11-8.
16. Kerschbaumer RJ, Riedrich K, Kral M, Varadi K, Dorner F, Rosing J, Scheiflinger F. An antibody specific for coagulation factor IX enhances the activity of the intrinsic factor X-activating complex. J Biol Chem 2004; 279: 40445-50.
17. Valentino LA, Scheiflinger F. Future aspects of hemophilia research and care. Semin Thromb Hemost 2006; 32 (Suppl. 2): 32-8.
18. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-7.
19. Jungbauer A, Tauer C, Reiter M, Purtscher M, Wenisch E, Steindl F, Buchacher A, Katinger H. Comparison of protein A, protein G and copolymerized hydroxyapatite for the purification of human monoclonal antibodies. J Chromatogr 1989; 476: 257-68.
20. Lollar P, Parker ET. Structural basis for the decreased procoagulant activity of human factor VIII compared to the porcine homolog. J Biol Chem 1991; 266: 12481-6.
21. Hemker HC, Beguin S. Thrombin generation in plasma: Its assessment via the endogenous thrombin potential. Thromb Haemost 1995; 74: 134-8.
22. Turecek PL, Varadi K, Gritsch H, Auer W, Pichler L, Eder G, Schwarz HP. Factor Xa and prothrombin: Mechanism of action of FEIBA. Vox Sang 1999; 77 (Suppl. 1): 72-9.
23. Kaufman RJ, Wasley LC, Dorner AJ. Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem 1988; 263: 6352-62.
24. Hedner U, Bjoern S, Bernvil SS, Tengborn L, Stigendahl L. Clinical experience with human plasma-derived factor VIIa in patients with hemophilia A and high titer inhibitors. Haemostasis 1989; 19: 335-43.
25. Barrowcliffe TW, Raut S, Sands D, Hubbard AR. Coagulation and chromogenic assays of factor VIII activity: General aspects, standardization, and recommendations. Semin Thromb Hemost 2002; 28: 247-56.
26. Gao C, Mao S, Lo CH, Wirsching P, Lerner RA, Janda KD. Making artificial antibodies: A format for phage display of combinatorial heterodimeric arrays. Proc Natl Acad Sci USA 1999; 96: 6025-30.